A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer

Heregulins (HRGs) bind to the receptors HER3 or HER4, induce receptor dimerization, and trigger downstream signaling that leads to tumor progression and resistance to targeted therapies. Increased expression of HRGs has been associated with worse clinical prognosis; therefore, attempts to block HRG-...

Descripción completa

Detalles Bibliográficos
Autores principales: Mota, Jose Mauricio, Collier, Katharine Ann, Barros Costa, Ricardo Lima, Taxter, Timothy, Kalyan, Aparna, Leite, Caio A., Chae, Young Kwang, Giles, Francis J., Carneiro, Benedito A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687690/
https://www.ncbi.nlm.nih.gov/pubmed/29179520
http://dx.doi.org/10.18632/oncotarget.18467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687690/
https://www.ncbi.nlm.nih.gov/pubmed/29179520
http://dx.doi.org/10.18632/oncotarget.18467

Ejemplares similares